NPPA directs strict monitoring of Trade Margin Rationalisation (TMR) on 137 non-scheduled anti-cancer drugs; State Drug Controllers to submit Action Taken Reports by 16 November 2026
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals of the Ministry of Chemicals and Fertilizers, has directed strict monitoring of the implementation of Trade Margin Rationalisation (TMR) on 137 non-scheduled anti-cancer drugs, notified vide Gazette Order dated 17 October 2026, with revised prices effective from 9 November 2026, according to a release of 13 November 2026. The latest revised price lists, based on submissions received from companies up to 11 November 2026, are available on the NPPA website and the Pharma Sahi Daam app/portal. All manufacturers, retailers, dealers, stockists, hospitals and medical institutions have been directed to comply with the revised prices and prominently display the updated price lists at their premises and websites. State Drug Controllers (SDCs) have been directed to strictly monitor compliance by manufacturers, dealers, hospitals and medical institutions to ensure that the benefits of revised MRPs are passed on to patients, and any violation may attract overcharging proceedings under the provisions of DPCO, 2013. Complaints regarding overcharging, shortage or non-availability of medicines can be reported through the Pharma Sahi Daam app/portal, the NPPA helpline (1800-111-255) or email. State Drug Controllers have been asked to submit their Action Taken Reports to NPPA by 16 November 2026.
Drafted with AI assistance from the official PIB release linked above and checked against it by a second AI pass. Not line-edited by a human. Published by Mahesh Srivastava, who corrects any error you report.
Learning context
NPPA has applied trade margin rationalisation to anti-cancer drugs before. A Ministry of Chemicals & Fertilizers release of 08 March 2019 said that on 27th February, 2019 NPPA had put 42 anti-cancer drugs under a 30% Trade Margin cap, and that manufacturers and hospitals were directed to convey revised MRPs, effective from 8th March, 2019, based on the Trade Margin formula. NPPA then put out a list of 390 anti-cancer non-scheduled medicines with MRP reduction up to 87%: 390 brands, i.e. 91% of the 426 brands reported by manufacturers, showed downward price movement, 38 of them by 75% and above. The release said the average out-of-pocket expenditure for cancer patients is 2.5 times that for other diseases, and that the move was expected to benefit 22 lakh cancer patients and result in annual savings of approx. Rs. 800 crores to consumers. The TMR for the 42 drugs was rolled out as a Proof of Concept, stressing a new paradigm of self-regulation by the industry, and their manufacturers were directed not to reduce production volumes of brands under regulation.
Check yourself: according to the March 2019 release, on what date had NPPA put anti-cancer drugs under a Trade Margin cap, how many drugs did it cover, and what was the cap?
27th February, 2019; 42 anti-cancer drugs; a 30% Trade Margin cap.
Revision task: from this release, note the authority and its parent department, the number of drugs covered, the Gazette Order date, the date the revised prices took effect, where the price lists are published, what State Drug Controllers must do and by when, and the order under which overcharging is pursued; from the note, the date and size of the 2019 trade margin cap, the number of brands whose prices fell and the expected benefit to patients.
Test yourself
By what date have State Drug Controllers been asked to submit their Action Taken Reports to NPPA on the implementation of Trade Margin Rationalisation on 137 non-scheduled anti-cancer drugs?
Show the answer
Answer: 16 November 2026
The release says State Drug Controllers have been asked to submit their Action Taken Reports to NPPA by 16 November 2026. The TMR on the 137 drugs was notified vide Gazette Order dated 17 October 2026, the revised prices took effect from 9 November 2026, and the latest price lists are based on company submissions up to 11 November 2026.
Read the daily collection → · Editorial standards & corrections